Gina Z. D'Amato, MD

Gina Z. D’Amato, MD, a professor of clinical medicine, assistant director of clinical research, medical director of the Nurse Practitioner Oncology Fellowship Program, and medical director of patient education at the Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami.

Articles

Dr D’Amato on the Rationale for Studying Olaparib/Temozolomide in Leiomyosarcoma

August 28th 2025

Gina Z. D’Amato, MD, discusses the rationale for investigating olaparib plus temozolomide in previously treated advanced uterine leiomyosarcoma.

Supporting Community Practice Through Collaboration

July 15th 2025

Panelists discuss how communication between community oncologists and academic centers is essential for advancing gastrointestinal stromal tumor (GIST) treatment through clinical trial participation, molecular analysis, and the promising future of personalized therapy based on individual tumor mutation profiles.

Dr D'Amato on Efficacy Data With Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

July 10th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Evolving Gastrointestinal Stromal Tumor Treatment Landscape

July 8th 2025

Panelists discuss how newer clinical trials such as PEAK and INSIGHT are investigating combination therapies and mutation-specific treatment approaches to overcome secondary resistance mutations, while also exploring pan-KIT inhibitors and senescence-targeting strategies to improve outcomes.

Ripretinib Use in Advanced Gastrointestinal Stromal Tumors

July 8th 2025

Panelists discuss how most gastrointestinal stromal tumor (GIST) patients can tolerate approved agents with proper adverse effect management, the efficacy data from the INVICTUS and INTRIGUE trials that led to ripretinib's approval, and the unique adverse effects such as alopecia that distinguish ripretinib from other therapies.

Treating Patients With Gastrointestinal Stromal Tumors

June 27th 2025

Panelists discuss how patient adherence to kinase inhibitors is crucial for disease control, requiring proactive adverse effect management, careful radiological monitoring, and strategies such as dose escalation to maximize treatment duration and effectiveness.

Gastrointestinal Stromal Tumor Treatment Landscape

June 27th 2025

Panelists discuss how standard-of-care treatment follows NCCN guidelines with sequential kinase inhibitor therapy (imatinib, sunitinib, regorafenib, ripretinib), emphasizing that maintaining some form of kinase inhibition is always preferable to no treatment even after progression.

Role of Mutations in Gastrointestinal Stromal Tumors

June 20th 2025

Panelists discuss how mutational testing is critical for gastrointestinal stromal tumor (GIST) management, with different genetic alterations determining treatment sensitivity and the importance of understanding both primary drivers and secondary resistance mutations that develop over time.

Overview of Gastrointestinal Stromal Tumors

June 20th 2025

Panelists discuss how gastrointestinal stromal tumors (GISTs) are the most common sarcoma with specific genetic mutations, requiring comprehensive mutational analysis to guide treatment decisions and understand both primary and secondary resistance patterns.

Dr D'Amato on the Implications of Data With Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

June 16th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Dr. D’Amato on Optimizing Treatment for Patients With Desmoid Tumors

November 18th 2021

Gina Z. D’Amato, MD, discusses optimizing treatment for patients with desmoid tumors.

Dr. D’Amato on the Importance of Multidisciplinary Care in Sarcoma

October 30th 2020

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Dr. D’Amato on the Limitations of Liquid Biopsy in Sarcoma

October 21st 2020

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Dr. D’Amato on the Diminishing Role of Chemotherapy in Sarcoma

October 9th 2020

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.

Dr. D'Amato on the Utility of NGS in Stage I, II, and III Sarcoma

August 19th 2020

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

Dr. D'Amato on the Emerging Role of Next-Generation Sequencing in Sarcoma

April 11th 2020

Gina Z. D'Amato, MD, discusses the emerging role of next-generation sequencing in sarcoma.

x